Positive Patient Stories™

Investor Overview

Webcast ImageWebcast - Replay
Paratek Pharmaceuticals, Inc. R&D Day
11/17/16 at 1:00 p.m. ET
Paratek Pharmaceuticals, Inc. R&D Day
Thursday, November 17, 2016 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$13.40
Change (%) Stock is Down 0.25 (1.83%)
Volume31,659
Data as of 12/06/16 12:35 p.m. ET

Latest News

11/02/16
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Clinical Updates
10/26/16
Paratek Pharmaceuticals, Inc. to Host R&D Day on November 17, 2016
10/24/16
Paratek Pharmaceuticals to Report Third Quarter 2016 Financial Results and Provide Update on Clinical Progress on November 2, 2016
10/11/16
Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.